首頁 > 市場調查報告書 > 製藥

癌症

市場調查報告書

商品編碼

1508768

膽管癌市場：依治療類型、通路和地區分類

Bile Duct Cancer Market, By Treatment Type (Chemotherapy, Targeted Therapy, Immunotherapy, Others), By Distribution Channel, By Geography

出版日期: 2024年06月14日 | 出版商:

Coherent Market Insights | 英文 184 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計2024年全球膽管癌市場規模為37.1億美元，預計2031年將達65.2億美元，2024年至2031年複合年成長率為8.4%。

圖 1. 2024 年按地區分類的膽管癌市場佔有率(%)

膽管癌是一種在膽管中形成的罕見癌症。膽管是連接肝臟、膽囊和小腸的管道。當膽管內壁細胞變得異常且不受控制地生長，形成腫瘤時，就會發生膽管癌。發生膽管癌的主要危險因子包括原發性硬化性膽管炎（PSC）、發炎性腸道疾病疾病、肝臟疾病和某些膽管先天缺陷。症狀包括黃疸、搔癢、腹痛、體重減輕和大便蒼白。診斷通常涉及影像學切片檢查，例如超音波、電腦斷層掃描、MRI 掃描或活體組織切片。治療選擇取決於癌症的階段，包括手術、放射線治療、化療和標靶治療。然而，膽管癌早期發現困難，腫瘤生長緩慢，存活率低，預後差。

市場動態：

全球膽管癌市場的成長主要是由PSC和肝炎等危險因子的盛行率不斷上升所推動的。據美國疾病管制與預防中心 (CDC) 稱，PSC 影響美國約 3 萬人。對膽管癌缺乏了解和延遲診斷也導致晚期診斷，推動市場成長。此外，增加針對標靶藥物開發的研究經費以改善膽管癌的治療效果也可能為市場相關人員提供利潤豐厚的機會。然而，疾病意識低和手術複雜性可能會阻礙市場成長。

本研究的主要特點

本報告對全球膽管癌市場進行了詳細分析，並給出了以2023年為基準年的預測期（2024-2031）的市場規模和年複合成長率（CAGR%）。
它還闡明了各個細分市場的潛在商機，並說明了該市場有吸引力的投資提案矩陣。
它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景、主要企業採取的競爭策略等的重要見解。
基於公司亮點、產品系列、主要亮點、績效和策略等參數的全球膽管癌市場主要企業的概況。
該報告的見解預計將使負責人和公司經營團隊能夠就未來的產品發布、類型升級、市場擴張和行銷策略做出明智的決策。
全球膽管癌市場報告迎合了該行業的各個相關人員，如投資者、供應商、產品製造商、經銷商、新進業者和財務分析師。
透過用於全球膽管癌市場分析的各種策略矩陣，將促進相關人員的決策。

公司簡介
- F. Hoffmann-La Roche Ltd
- Sanofi
- Pfizer Inc.
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- Merck &Co., Inc.
- Novartis AG
- Celgene Corporation
- Johnson &Johnson Services, Inc.
- Teva Pharmaceutical Industries Ltd.
- Bayer AG
- Fresenius Kabi AG
- Mylan NV
- ConMed Corporation
- Boston Scientific Corporation
- Taiho Pharmaceutical Co., Ltd.
- Incyte Corporation

第9章分析師建議

升起和降落
綜合機會圖
參考文獻與調查方法
參考
調查方法

簡介目錄

Product Code: CMI4790

Global bile duct cancer market is estimated to be valued at US$ 3.71 Bn in 2024 and is expected to reach US$ 6.52 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 8.4% from 2024 to 2031.

Figure 1. Bile Duct Cancer Market Share (%), By Region, 2024

Bile duct cancer, also known as cholangiocarcinoma, is a rare type of cancer that forms in the bile duct. The bile duct is a tube that connects the liver and gallbladder to the small intestine. Bile duct cancer occurs when the cells that line the bile ducts become abnormal and grow uncontrollably, forming a tumor. Key risk factors for developing bile duct cancer include primary sclerosing cholangitis (PSC), an inflammatory bowel disease, liver flukes, and certain congenital abnormalities of the bile ducts. Symptoms may include jaundice, itching, abdominal pain, weight loss, and pale stools. Diagnosis usually involves imaging tests such as ultrasound, CT scan, and MRI scans, as well as biopsy. Treatment options depend on the stage of cancer and include surgery, radiation therapy, chemotherapy, and targeted therapy. However, bile duct cancer has a poor prognosis with low survival rates due to difficulties in early detection and slow growth nature of the tumors.

Market Dynamics:

Global bile duct cancer market growth is primarily driven by increasing prevalence of risk factors such as PSC and liver flukes infections. According to the Center for Disease Control and Prevention (CDC), PSC affects around 30,000 people in the U.S. Insufficient understanding and delays in diagnosing bile duct cancer also contribute to late-stage diagnosis, thus, driving the market growth. Moreover, rising research funding towards targeted drug development for improving the bile duct cancer treatment outcomes can offer lucrative opportunities for market players. However, low disease awareness and complexity in surgical procedures can hamper the market growth.

Key Features of the Study:

This report provides in-depth analysis of the global bile duct cancer market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global bile duct cancer market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Eli Lilly, F. Hoffmann-La Roche Ltd., Pfizer Inc., Sanofi, and Bristol-Myers Squibb Company
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global bile duct cancer market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global bile duct cancer market

Detailed Segmentation-

By Treatment Type
- Chemotherapy
- Gemcitabine
- Cisplatin
- Oxaliplatin
- Capecitabine
- 5 fluorouracil (5-FU)
- Targeted Therapy
- Pemigatinib
- Infigratinib (Phase 3)
- Ivosidenib (Phase 3)
- Immunotherapy
- (Pembrolizumab (Phase 3))

Others

By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
Company Profiles:
- Hoffmann-La Roche Ltd
- Sanofi
- Pfizer Inc.
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- Merck & Co., Inc.
- Novartis AG
- Celgene Corporation
- Johnson & Johnson Services, Inc.
- Teva Pharmaceutical Industries Ltd.
- Bayer AG
- Fresenius Kabi AG
- Mylan N.V.
- ConMed Corporation
- Boston Scientific Corporation
- Taiho Pharmaceutical Co., Ltd.
- Incyte Corporation

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Treatment Type
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Opportunities
Impact Analysis
Market Trends
Key Developments
Regulatory Scenario
Acquisitions and Partnerships Scenario
Funding and Investments
PEST Analysis
Porter's Analysis

4. Global Bile Duct Cancer Market - Impact of Coronavirus (COVID-19) Pandemic

Overall Impact
Government Initiatives
COVID-19 Impact on the Market

5. Global Bile Duct Cancer Market, By Treatment Type, 2019 - 2031, (USD Bn)

Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Chemotherapy
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Gemcitabine
- Cisplatin
- Oxaliplatin
- Capecitabine
- 5 fluorouracil (5-FU)
Targeted Therapy
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Pemigatinib
- Infigratinib (Phase 3)
- Ivosidenib (Phase 3)
Immunotherapy
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- (Pembrolizumab (Phase 3)
Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

6. Global Bile Duct Cancer Market, By Distribution Channel, 2019 - 2031, (USD Bn)

Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Hospital Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Retail Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Online Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

7. Global Bile Duct Cancer Market, By Region, 2019 - 2031, (USD Bn)

Introduction
- Market Share Analysis, By Region, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, For Region, 2020-2031
- Regional Trends
  - North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
  - GCC
  - Israel
  - Rest of Middle East
  - Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019 - 2031, (USD Bn)
  - North Africa
  - Central Africa
  - South Africa

8. Competitive Landscape

Company Profiles
- F. Hoffmann-La Roche Ltd
  - Company Highlights
  - Method Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Sanofi
  - Company Highlights
  - Method Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Pfizer Inc.
  - Company Highlights
  - Method Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Bristol-Myers Squibb Company
  - Company Highlights
  - Method Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Eli Lilly and Company
  - Company Highlights
  - Method Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Merck & Co., Inc.
  - Company Highlights
  - Method Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Novartis AG
  - Company Highlights
  - Method Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Celgene Corporation
  - Company Highlights
  - Method Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Johnson & Johnson Services, Inc.
  - Company Highlights
  - Method Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Teva Pharmaceutical Industries Ltd.
  - Company Highlights
  - Method Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Bayer AG
- Fresenius Kabi AG
- Mylan N.V.
- ConMed Corporation
- Boston Scientific Corporation
- Taiho Pharmaceutical Co., Ltd.
- Incyte Corporation

9. Analyst Recommendations

Wheel of Fortune
Analyst View
Coherent Opportunity Map
References and Research Methodology
References
Research Methodology
About us and Sales Contact

02-2729-4219

+886-2-2729-4219

License/價格

相關商品

全球膽管癌藥物市場研究報告 - 2024 年至 2032 年產業分析、規模、佔有率、成長、趨勢與預測

膽管癌市場：依癌症類型、治療類型、給藥途徑、配銷通路及地區分類

膽管癌治療藥的全球市場調查報告-產業分析，規模，佔有率，成長，趨勢，2022年～2028年前的預測

FAQ

膽管癌市場：依治療類型、通路和地區分類